Galectin Therapeutics Inc. (GALT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Galectin Therapeutics Inc. (GALT) closed at USD 3.71 on 2026-10-15, a change of -27.4 % over the past year, with a market capitalization of USD 365.08M.

Galectin Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Galectin Therapeutics Inc. key figures

Previous close

USD 3.71 (2026-10-15)

1-year change

-27.4 %

Market cap

USD 365.08M

Enterprise value

USD 497.96M

P/E ratio (trailing)

-8.42

P/E ratio (forward)

-2.16

EPS (trailing)

-0.43

EPS (forward)

-1.68

PEG ratio

-36.15

Price to book

-1.73

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

29.01

Employees

9

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Galectin Therapeutics Inc. and compare it with other stocks.